Abstract
Introduction
In 2008, antiretroviral sales across the seven major markets totaled $10.7
billion, growing at a CAGR of 12.8% between 2005 and 2008. Datamonitor expects
this expansion to slow down. Despite drivers such as new product launches,
earlier treatment initiation, decreasing mortality and an increase in HIV
prevalence, a series of patent expiries will impact branded sales from 2011.
Key reasons to purchase this research
- Understand the changing market dynamics of HIV drugs, success factors for
leading brands and the commercial potential of late stage pipeline products
- Assess the impact of events such as patent expiries and new product
launches on individual brands and the overall antiretroviral market.
- Obtain full global, country, class and product-specific forecasts of
currently marketed and pipeline antiretrovirals from 2008 to 2018.
Table of Contents
OVERVIEW
- This product contains forecasts for HIV drugs across the seven major
markets from 2009 to 2018. It has been designed for delivery in an excel data
pack format, but for more detail about this disease area please see the
accompanying Forecast Insight: HIV word document (DMHC2518).
- The associated report can be found under Latest research in the
Knowledge centre, through the search function or by contacting your sales
representative.
- Please select the data pack option from the download menu at the side of
the page to access the model.
- Introduction
- Scope of this research
- Research and analysis highlights
- Key reasons to read this report
- Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
| 
